Clinical Trial Update: Observational Study on Second Line Treatment of Liver Metastases With DEBIRI and Cetuximab

View source ↗

Summary

Observational trial update examining second-line treatment of colorectal cancer liver metastases with DEBIRI and cetuximab; the study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Liver Metastasis

Drugs mentioned

• DEBIRI (irinotecan-loaded drug-eluting beads)
• ERBITUX (cetuximab)

Snippet

Sponsor: International Group of Endovascular Oncology | Conditions: Colon Cancer Liver Metastasis | Status: COMPLETED